FLGT
Fulgent Genetics, Inc.
$18.31
-4.39%
$525.4M
No data for this timeframe.
Vol
Market Cap$525.4M
Cap SizeSmall Cap
Analyst ConsensusSell (0%)
Inst. Holders8 funds
Inst. Value$69.2M
Inst. Activity3 buys / 1 sells
Insider Activity0B / 4S
Insider Net $-$106.3K
Reddit Sentiment50° Neutral
SEC Reports3
Recent Activity
Jun 3, 2026
SEC
A cluster of insider selling at Fulgent Genetics: the President/COO sold ~$21K and the CSO sold ~$17K in open-market tra
CLUSTER — Impact 2/10
Jun 2, 2026
Insider
Gao Hanlin sold 1,688 shares
Chief Scientific Officer @ $17.89 ($30.2K)
Jun 2, 2026
Insider
Xie Jian sold 2,146 shares
President and COO @ $17.89 ($38.4K)
Jun 1, 2026
Insider
Hsieh Ming sold 4,392 shares
Chief Executive Officer @ $18.09 ($79.5K)
May 28, 2026
SEC
Two C-suite insiders at Fulgent Genetics (President/COO and CSO) made open-market sales totaling ~$38K on May 27, 2026,
CLUSTER — Impact 3/10
May 21, 2026
SEC
Fulgent Genetics announced interim Phase 2 data for FID-007 + cetuximab in R/M HNSCC, showing a 60% objective response r
8-K — Impact 7/10
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
297,355 shares ($7.8M)
Inst.
WELLS FARGO & COMPANY/MN — DOUBLED
120,781 shares ($3.2M)
Price Targets
$18.50
+0.0% upside
Hold
Current $18.50
Low $15.00
Median $18.50
High $22.00
2 analysts
$15.00
$22.00
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | Piper Sandler | REITERATE | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.44 ▼ -38.3% | $-0.46 — $-0.42 | -727% YoY | 2 |
| Next Q | $-0.37 ▼ -45.5% | $-0.38 — $-0.36 | -363% YoY | 2 |
| Current FY | $-1.57 ▼ -11.5% | $-1.59 — $-1.55 | -473% YoY | 2 |
| Next FY | $-1.53 ▼ -2.9% | $-1.91 — $-1.15 | 3% YoY | 2 |
Latest Reports
NEUTRAL
CLUSTER
2/10
A cluster of insider selling at Fulgent Genetics: the President/COO sold ~$21K and the CSO sold ~$17K in open-market tra
Jun 3, 2026
NEUTRAL
CLUSTER
3/10
Two C-suite insiders at Fulgent Genetics (President/COO and CSO) made open-market sales totaling ~$38K on May 27, 2026,
May 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $33.1M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $10.6M | NEW |
| MORGAN STANLEY | $8.3M | TRIM |
| TWO SIGMA INVESTMENTS, LP | $7.8M | ADD |
| BANK OF AMERICA CORP | $4.0M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Gao Hanlin | SELL | $30.2K |
| Jun 2, 2026 | Xie Jian | SELL | $38.4K |
| Jun 1, 2026 | Hsieh Ming | F | $79.5K |
| Jun 1, 2026 | Kim Paul | F | $37.8K |
| May 27, 2026 | Gao Hanlin | SELL | $16.6K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
8 institutional holders with $69.2M total value (2,635,952 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, MORGAN. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,260,014 | $33.1M | 47.8% | — |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 402,802 | $10.6M | 15.3% | NEW |
| 3 | MORGAN STANLEY | 315,253 | $8.3M | 12.0% | TRIM -66.8% |
| 4 | TWO SIGMA INVESTMENTS, LP | 297,355 | $7.8M | 11.3% | ADD +88.7% |
| 5 | BANK OF AMERICA CORP /DE/ | 152,902 | $4.0M | 5.8% | ADD +67.1% |
| 6 | WELLS FARGO & COMPANY/MN | 120,781 | $3.2M | 4.6% | DOUBLED +261.1% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 82,864 | $2.2M | 3.1% | NEW |
| 8 | FMR LLC | 3,981 | $104.6K | 0.2% | TRIM -64.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 157,608 | 297,355 | +88.7% | $7.8M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 33,452 | 120,781 | +261.1% | $3.2M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 82,864 | — | $2.2M | 2025-Q4 |
| FMR LLC | TRIM | 11,304 | 3,981 | -64.8% | $104.6K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 93,719 | 157,608 | +68.2% | $3.6M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 93,525 | 156,251 | +67.1% | $3.5M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 47,480 | 33,452 | -29.5% | $756.0K | 2025-Q3 |
| UBS Group AG | TRIM | 76,223 | 21,489 | -71.8% | $485.7K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 53,104 | 93,719 | +76.5% | $1.9M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 144,077 | 93,525 | -35.1% | $1.9M | 2025-Q2 |
| UBS Group AG | DOUBLED | 18,572 | 76,223 | +310.4% | $1.5M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 377,533 | 47,480 | -87.4% | $943.9K | 2025-Q2 |
| FMR LLC | DOUBLED | 1,163 | 11,572 | +895.0% | $230.0K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 10,400 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 297,819 | 529,542 | +77.8% | $8.9M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | TRIM | 1,314,010 | 377,533 | -71.3% | $6.4M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 541,972 | 180,138 | -66.8% | $3.0M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 80,082 | 53,104 | -33.7% | $897.5K | 2025-Q1 |
| UBS Group AG | TRIM | 52,560 | 18,572 | -64.7% | $313.9K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 24,900 | 10,400 | -58.2% | $175.8K | 2025-Q1 |
| FMR LLC | TRIM | 4,298 | 1,163 | -72.9% | $19.7K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 1,011,521 | 1,314,010 | +29.9% | $24.3M | 2024-Q4 |
| UBS Group AG | DOUBLED | 9,912 | 52,560 | +430.3% | $970.8K | 2024-Q4 |
| MORGAN STANLEY | ADD | 369,133 | 467,332 | +26.6% | $10.2M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 245,188 | — | $5.3M | 2024-Q3 |
7 unique insiders with 4 transactions. Net insider value: -$106.3K ($0.00 bought, $106.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Gao Hanlin | Chief Scientific Officer | SELL | 1,688 | $17.89 | $30.2K |
| Jun 2, 2026 | Xie Jian | President and COO | SELL | 2,146 | $17.89 | $38.4K |
| Jun 1, 2026 | Hsieh Ming | Chief Executive Officer | F | 4,392 | $18.09 | $79.5K |
| Jun 1, 2026 | Kim Paul | CFO and Treasurer | F | 2,087 | $18.09 | $37.8K |
| May 27, 2026 | Gao Hanlin | Chief Scientific Officer | SELL | 945 | $17.60 | $16.6K |
| May 27, 2026 | Xie Jian | President and COO | SELL | 1,201 | $17.60 | $21.1K |
| May 26, 2026 | Hsieh Ming | Chief Executive Officer | F | 2,949 | $17.67 | $52.1K |
| May 26, 2026 | Kim Paul | CFO and Treasurer | F | 1,168 | $17.67 | $20.6K |
| May 14, 2026 | GROVES REGINA E | Director | A | 11,117 | $0.00 | $0.00 |
| May 14, 2026 | Dong Linda | Director | A | 11,117 | $0.00 | $0.00 |
| May 14, 2026 | Nohaile Michael | Director | A | 5,558 | $0.00 | $0.00 |
| May 14, 2026 | Nohaile Michael | Director | A | 8,426 | $0.00 | $0.00 |
| Apr 26, 2026 | Kim Paul | CFO and Treasurer | F | 2,747 | $16.31 | $44.8K |
| Apr 26, 2026 | Xie Jian | President and COO | F | 4,361 | $16.31 | $71.1K |
| Apr 26, 2026 | Gao Hanlin | Chief Scientific Officer | F | 1,645 | $16.31 | $26.8K |
| Mar 9, 2026 | Hsieh Ming | Chief Executive Officer | J | 750,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Hsieh Ming | Chief Executive Officer | J | 750,000 | $0.00 | $0.00 |
| Mar 1, 2026 | Xie Jian | President and COO | F | 1,079 | $15.33 | $16.5K |
| Mar 1, 2026 | Gao Hanlin | Chief Scientific Officer | F | 1,018 | $15.33 | $15.6K |
| Mar 1, 2026 | Kim Paul | CFO and Treasurer | F | 1,133 | $15.33 | $17.4K |
| Mar 1, 2026 | Hsieh Ming | Chief Executive Officer | F | 17,566 | $15.33 | $269.3K |
| Feb 26, 2026 | Gao Hanlin | Chief Scientific Officer | F | 897 | $24.76 | $22.2K |
| Feb 26, 2026 | Kim Paul | CFO and Treasurer | F | 1,168 | $24.76 | $28.9K |
| Feb 26, 2026 | Hsieh Ming | Chief Executive Officer | F | 2,949 | $24.76 | $73.0K |
| Feb 26, 2026 | Xie Jian | President and COO | F | 1,140 | $24.76 | $28.2K |
| Feb 24, 2026 | Kim Paul | CFO and Treasurer | A | 5,721 | $0.00 | $0.00 |
| Feb 24, 2026 | Xie Jian | President and COO | A | 5,862 | $0.00 | $0.00 |
| Feb 24, 2026 | Gao Hanlin | Chief Scientific Officer | A | 4,891 | $0.00 | $0.00 |
| Feb 24, 2026 | Hsieh Ming | Chief Executive Officer | A | 19,067 | $0.00 | $0.00 |
| Feb 23, 2026 | Kim Paul | CFO and Treasurer | F | 661 | $23.01 | $15.2K |
| Feb 23, 2026 | Gao Hanlin | Chief Scientific Officer | F | 403 | $23.01 | $9.3K |
| Feb 23, 2026 | Xie Jian | President and COO | F | 655 | $23.01 | $15.1K |
| Feb 23, 2026 | Hsieh Ming | Chief Executive Officer | F | 2,167 | $23.01 | $49.9K |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.0/10.
NEUTRAL
CLUSTER
2/10
A cluster of insider selling at Fulgent Genetics: the President/COO sold ~$21K and the CSO sold ~$17
Jun 3, 2026
NEUTRAL
CLUSTER
3/10
Two C-suite insiders at Fulgent Genetics (President/COO and CSO) made open-market sales totaling ~$3
May 28, 2026
BULLISH
8-K
7/10
Fulgent Genetics announced interim Phase 2 data for FID-007 + cetuximab in R/M HNSCC, showing a 60%
May 21, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Sell (0% buy). Based on 6 analysts: 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell.
Analyst Price Targets
$18.50 mean target
+0.0% upside
Hold (3.00)
$15.00 Low
$22.00 High
| Metric | Value |
|---|---|
| Current Price | $18.50 |
| Target Low | $15.00 |
| Target Mean | $18.50 |
| Target Median | $18.50 |
| Target High | $22.00 |
| # Analysts | 2 |
| Recommendation | Hold (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.44 | $-0.46 | $-0.42 | -726.9% | -38.3% | 0↑ 1↓ | $0.1B | 12.2% | 2 |
| Next Q 2026-09-30 |
$-0.37 | $-0.38 | $-0.36 | -362.9% | -45.5% | — | $0.1B | 11.6% | 2 |
| Current FY 2026-12-31 |
$-1.57 | $-1.59 | $-1.55 | -473.4% | -11.5% | 0↑ 1↓ | $0.4B | 8.8% | 2 |
| Next FY 2027-12-31 |
$-1.53 | $-1.91 | $-1.15 | 2.6% | -2.9% | 0↑ 1↓ | $0.4B | 14.6% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.439 | |
| 7d ago | $-0.281 | -0.158 |
| 30d ago | $-0.317 | -0.121 |
| 60d ago | $-0.317 | -0.121 |
| 90d ago | $-0.077 | -0.362 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | Piper Sandler | REITERATE | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| May 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Feb 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Jan 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
1 bullish
1 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 1, 2026
earnings_calendar
FLGT Q1 2026 Earnings Before Market Open — 2026-05-01
Feb 27, 2026
earnings_calendar
FLGT Q4 2025 Earnings After Market Close — 2026-02-27